Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lomitapide - Amryt Pharma/University of Pennsylvania

Next Previous
X
Search
Drug Profile

Lomitapide - Amryt Pharma/University of Pennsylvania

Alternative Names: AEGR-733; BMS-201038; JUXTAPID; Juxtapid; Lojuxta

Latest Information Update: 22 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Amryt Pharma; University of Pennsylvania
  • Class Antihyperlipidaemics; Benzamides; Biphenyl compounds; Fluorenes; Piperidines; Small molecules
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type IIa
  • Phase III Hyperlipoproteinaemia type I

Most Recent Events

  • 06 Jun 2024 Amryt Pharma completes a phase III trial in Hyperlipoproteinaemia type IIa (Adjunctive treatment, In adolescents, In children) in Israel, Tunisia, Spain, Saudi Arabia, Italy (PO) (NCT04681170)
  • 12 Apr 2023 Amryt Pharma has been acquired by Chiesi Farmaceutici
  • 05 Jan 2023 Efficacy and adverse events data from a phase III trial in Hyperlipoproteinaemia type IIa released by Amryt Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top